Overall, our study highlights the potential clinical application of SGLT2 inhibition in the prevention of obesity and related metabolic diseases, such as insulin resistance, NAFLD, and diabetes. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.